Loading stock data…
Cellectis S.A (CLLS)
$2.94+0.11 (+3.89%)
Market ClosedLast close Jun 29
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cellectis S.A. in the Healthcare sector is trading at $2.94 with a market capitalization of $320M. Wall Street consensus targets $7.60 (5 analysts), implying a +158.5% move over the next 12 months. The stock is currently 46% below its 52-week high of $5.48, remaining 23.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +158.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.78M↓ | $10.40M↓ | $35.17M↑ | $16.73M↑ | $10.65M |
| Gross Profit | $3.46M↓ | $7.40M↓ | $32.81M↑ | $14.30M↑ | $8.64M |
| Operating Income | -$25.17M↓ | -$17.35M↓ | $8.04M↑ | -$9.59M↑ | -$14.18M |
| Net Income | -$17.77M↑ | -$26.32M↓ | $589,000↑ | -$23.73M↓ | -$18.13M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$319.71M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-112.20%
Volume
Today's trading volume
21,814
Recent News
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading
European equities traded in the US as American depositary receipts were trending higher late Monday
European Equities Traded in US as ADRs Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning with t
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
European equities traded in the US as American depositary receipts were lower late Wednesday morning
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts started the week higher late Mond
European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading
European equities traded in the US as American depositary receipts were down marginally late Thursda